Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivarmacitinib Combined With Camrelizumab and Fruquintinib for Patients With Metastatic Colorectal Cancer
NCT07896096Phase 2Recruiting
- Sponsor
- Renmin Hospital of Wuhan University
- Start
- Apr 2026
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ivarmacitinib in colorectal cancer (CRC), sponsored by Renmin Hospital of Wuhan University. Primary endpoints: Progression-Free Survival at 1 year, Objective Response Rate at 1 year and 1 more. Started Apr 2026; status: recruiting.
02
Drugs
ivarmacitinib
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT07896096.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07896096.